The CEO of SkinBioTherapeutics plc has resigned over 鈥榤atters relating to his conduct鈥�.
Stuart Ashman was suspended by the listed Newcastle firm鈥檚 board prior to the resignation and it has promised a full investigation.
The life science HealthTech, which is focused on skin heath, said non-executive chair Martin Hunt will temporarily become executive chair.
鈥淗e will be supported by the rest of the board and leadership team to provide business leadership and continuity,鈥� SkinBioTherapeutics said in a notice to the London Stock Exchange.
鈥淭he company has instigated a search to find an interim CEO to appoint as soon as possible, and to find a new, permanent CEO for the longer term.鈥�
Ashman was appointed in 2024, succeeding Professor Cath O鈥橬eill, with over two decades of commercial healthcare experience – primarily in the medical devices industry.
Since 2014, he had served as CEO of Onbone, a Finnish private equity-backed medical device company.聽Prior to that, Ashman was president and CEO of Andover Healthcare, a US-based wound management manufacturer and president and CEO of TI Group, a UK-based medical/engineering company.
Last year the company welcomed a new COO and board member in Simon Hewitson, a former CEO of Polar Krush Group.
Emily Bertram was also appointed as the group’s finance director in a non-board capacity following the departure of Manprit Randhawa.
Key figures behind No.10鈥檚 COVID response raise 拢10m for startup